Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 4:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 10,450 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Kind Clear all
Active, not recruiting Phase 4 Interventional

Effects of Sitagliptin in Individuals With Genetically Decreased DPP4

NCT04323189
View directory record Official record
Conditions
Genetics Disease, Type2 Diabetes, Heart Failure
Interventions
Sitagliptin 100mg, Placebo Oral Tablet
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Oct 27, 2026, 4:35 PM EDT
Recruiting Phase 1 Interventional

A Study of Pembrolizumab and Ablation (Cryoablation or Histotripsy) in People With Breast Cancer

NCT06246968
View directory record Official record
Conditions
Metastatic Breast Cancer, Breast Cancer, Breast Cancer Stage IV, Triple Negative Breast Cancer, Triple Negative Breast Neoplasms, Metastatic Triple-Negative Breast Carcinoma, Locally Advanced Breast Cancer, Locally Advanced Triple-Negative Breast Carcinoma
Interventions
Pembrolizumab, Cryoablation, Histotripsy
Drug · Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 27, 2026, 4:35 PM EDT
Recruiting Phase 3 Interventional

Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes

NCT05819138
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Semaglutide Pen Injector, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 49 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Aurora, Colorado • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 27, 2026, 4:35 PM EDT
Recruiting Phase 2 Interventional

High vs. Standard Dose Influenza Vaccines in Lung Transplant (Repeater)

NCT07192458
View directory record Official record
Conditions
Immunization; Infection|Transplantation Infection|Influenza, Influenza
Interventions
Fluzone High Dose Inactivated Influenza Vaccine, Fluzone Standard Dose Inactivated Influenza Vaccine
Biological
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 27, 2026, 4:35 PM EDT
Completed Not applicable Interventional

UH3 Phase - Mindfulness-Based Blood Pressure Reduction (MB-BP) : Stage 2a RCT

NCT03859076
View directory record Official record
Conditions
Hypertension, Prehypertension
Interventions
MB-BP, Enhanced Usual Care Control
Behavioral · Other
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jan 13, 2021 · Synced Oct 27, 2026, 4:35 PM EDT
Not listed Phase 1 Interventional

Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.

NCT04519476
View directory record Official record
Conditions
Refractory Multiple Myeloma
Interventions
Selinexor, Lenalidomide, Methylprednisolone
Drug
Lead sponsor
Oncotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
West Hollywood, California
Source: ClinicalTrials.gov public record
Updated Oct 31, 2023 · Synced Oct 27, 2026, 4:35 PM EDT
Active, not recruiting No phase listed Observational

Prevalence of NAFLD and Advanced Fibrosis in Patients With Type 1 Diabetes

NCT04595474
View directory record Official record
Conditions
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis, Fibrosis, Liver, Type 1 Diabetes, Cirrhosis, Liver
Interventions
Transient Elastography
Device
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
18 Years to 75 Years
Enrollment
533 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 27, 2026, 4:35 PM EDT
Active, not recruiting Phase 1 Interventional

Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)

NCT04886804
View directory record Official record
Conditions
Neoplasm Metastasis, Non-Small Cell Lung Cancer
Interventions
zongertinib
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
554 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
20
States / cities
Birmingham, Alabama • Beverly Hills, California • Duarte, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 27, 2026, 4:35 PM EDT
Completed Not applicable Interventional Results available

Project Resurgence Communication Trial

NCT04418947
View directory record Official record
Conditions
Communication Research
Interventions
Communication type
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
Not listed
Enrollment
11,120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 27, 2026, 4:35 PM EDT
Completed No phase listed Observational

Ex Vivo Drug Sensitivity Testing and Mutation Profiling

NCT03860376
View directory record Official record
Conditions
Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Large Cell Lymphoma, Refractory Childhood Acute Lymphoblastic Leukemia, Refractory Childhood Hodgkin Lymphoma, Refractory Childhood Malignant Germ Cell Neoplasm, Recurrent Childhood Brain Tumor, Recurrent Childhood Brainstem Glioma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Childhood Ependymoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Gliosarcoma, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Interventions
Not listed
Lead sponsor
Florida International University
Other
Eligibility
1 Day to 21 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 10, 2023 · Synced Oct 27, 2026, 4:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Trial to Assess Gastrointestinal Responses to Dietary Fibers in Adults Using Weight Loss Medications

NCT07012317
View directory record Official record
Conditions
Gastrointestinal Symptoms, Weight Loss, GLP-1
Interventions
High Fiber Bar with Inulin, High Fiber bar with Fiber Blend, High Fiber Bar with Resistant Starch type 4, Low Fiber Bar
Other
Lead sponsor
Midwest Center for Metabolic and Cardiovascular Research
Other
Eligibility
25 Years to 64 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
2
States / cities
Miami Gardens, Florida • Port Saint Lucie, Florida
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 27, 2026, 4:35 PM EDT
Completed Not applicable Interventional

Graded Motor Imagery for Women at Risk for Developing Type I CRPS Following Closed Treatment of Distal Radius Fractures

NCT02957240
View directory record Official record
Conditions
Musculoskeletal Pain, Fractures, Closed, Distal Radius Fracture, Complex Regional Pain Syndromes
Interventions
Standard Care, Motor Representation Techniques
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
55 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Oct 27, 2026, 4:35 PM EDT
Completed Phase 2 Interventional

A Trial of BMS-512148 in Patients With Type 2 Diabetes Mellitus

NCT00263276
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
dapagliflozin, placebo, metformin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 79 Years
Enrollment
389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
111
States / cities
Bayou La Batre, Alabama • Birmingham, Alabama • Huntsville, Alabama + 107 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2016 · Synced Oct 27, 2026, 4:35 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Percutaneous Endoscopic Gastrostomy Versus Percutaneous Endoscopic Gastrostomy With Jejunal Extension

NCT06717321
View directory record Official record
Conditions
Aspiration Pneumonias, Tube Feeding, Enteral Feeds
Interventions
(Arm 1): PEG, (Arm 2): PEG-J
Procedure
Lead sponsor
Jerry Dang
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Oct 27, 2026, 4:35 PM EDT
Completed Not applicable Interventional Results available

Pilot Trial of the Nutrition-Supported Diabetes Education Program

NCT05067452
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Food support, Case-management
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Martinez, California
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Oct 27, 2026, 4:35 PM EDT
Terminated Phase 2 Interventional Results available

Pembrolizumab and Pelareorep in Treating Patients With Advanced Pancreatic Cancer

NCT03723915
View directory record Official record
Conditions
Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions
Pembrolizumab, Wild-type Reovirus
Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 5, 2022 · Synced Oct 27, 2026, 4:35 PM EDT
Withdrawn Phase 2 Interventional

4-Aminopyridine in Episodic Ataxia Type 2

NCT01543750
View directory record Official record
Conditions
Episodic Ataxia Type 2
Interventions
4-Aminopyridine, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
Los Angeles, California • Tampa, Florida • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 16, 2020 · Synced Oct 27, 2026, 4:35 PM EDT
Completed Phase 1 Interventional Results available

A Multiple Dose Study Of PF-04620110 In Type 2 Diabetes Patients

NCT01298518
View directory record Official record
Conditions
Type 2 Diabetes Patients
Interventions
PF-04620110, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 60 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
3
States / cities
Chula Vista, California • DeLand, Florida • Miami Gardens, Florida
Source: ClinicalTrials.gov public record
Updated Nov 6, 2012 · Synced Oct 27, 2026, 4:35 PM EDT
Recruiting Not applicable Interventional

LINK-IT: Leveraging vIdeos and commuNity Health worKers to Improve Diabetes OuTcomes

NCT06319716
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Video-Based Diabetes Self-Management Education and Support (DSMES), Community Health Worker (CHW) Support
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 27, 2026, 4:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of a Surgical Microscope Mounted Autorefractor When Used on Patients Lying in a Supine Position

NCT01827748
View directory record Official record
Conditions
Refractive Error
Interventions
Intraoperative Autorefractor IAR-1, Hartmann-Shack Auto Refractor
Device
Lead sponsor
Adventus Technology
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 12, 2013 · Synced Oct 27, 2026, 4:35 PM EDT
Completed Phase 2 Interventional Results available

Study Using IMC-A12 (Cixutumumab) With or Without Cetuximab in Participants With Metastatic Colorectal Cancer Who Have Failed a Treatment Regimen That Consisted of a Prior Anti-EGFR Therapy

NCT00503685
View directory record Official record
Conditions
Colorectal Cancer
Interventions
IMC-A12, cetuximab
Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
4
States / cities
Los Angeles, California • New Haven, Connecticut • Buffalo, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 27, 2026, 4:35 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Production of Free Fatty Acids From Blood Triglycerides

NCT00911482
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Insulin Resistance, Dyslipidemias
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
35 Years to 60 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 7, 2012 · Synced Oct 27, 2026, 4:35 PM EDT
Completed Phase 1Phase 2 Interventional

AC6 Gene Transfer for CHF

NCT00787059
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
Ad5.hAC6, Sucrose (3%)
Drug
Lead sponsor
Hammond, H. Kirk, M.D.
Individual
Eligibility
18 Years to 80 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
7
States / cities
San Diego, California • Chicago, Illinois • Minneapolis, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2018 · Synced Oct 27, 2026, 4:35 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Xeomin vs Botox for Treatment of Overactive Bladder Syndrome

NCT06034288
View directory record Official record
Conditions
Overactive Bladder Syndrome
Interventions
Xeomin 100 UNT Injection, Botox 100 UNT Injection
Drug
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years and older · Female only
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2023 · Synced Oct 27, 2026, 4:35 PM EDT